Under these conditions, pre-treatment of the tumor cells with the selective CD39- or CD73-inhibitors ARL67156 or APCP did not affect their viability, but reduced monocyte migration by more than half, as compared to the solvent control. This evidence concerns the gene NT5E and neoplasm.